{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T19:57:46Z","timestamp":1781294266662,"version":"3.54.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.dld.2021.06.023","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T04:59:01Z","timestamp":1626757141000},"page":"154-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"54","author":[{"given":"Luca","family":"Valenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pedica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dld.2021.06.023_bib0001","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2021.06.023_bib0002","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.dld.2021.06.023_bib0003","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.dld.2021.06.023_bib0004","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.dld.2021.06.023_bib0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.14218\/JCTH.2015.00023","article-title":"TM6SF2 E167K variant, a novel genetic susceptibility variant, contributing to nonalcoholic fatty liver disease","volume":"3","author":"Chen","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.dld.2021.06.023_bib0006","doi-asserted-by":"crossref","first-page":"460190","DOI":"10.1155\/2015\/460190","article-title":"Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis","volume":"2015","author":"Dongiovanni","year":"2015","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.dld.2021.06.023_bib0007","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J. Hepatol."},{"issue":"17","key":"10.1016\/j.dld.2021.06.023_bib0008","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.dld.2021.06.023_bib0009","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","article-title":"Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma","volume":"126","author":"El-Serag","year":"2004","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.dld.2021.06.023_bib0010","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from chronic liver diseases in diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0011","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/liv.13031","article-title":"The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment","volume":"36","author":"Margini","year":"2016","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.dld.2021.06.023_bib0012","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0013","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/hep.30161","article-title":"Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States","volume":"69","author":"Kim","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000002361","article-title":"Should patients with NAFLD\/NASH be surveyed for HCC?","volume":"103","author":"Reig","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2021.06.023_bib0015","doi-asserted-by":"crossref","unstructured":"J.G. Stine, B.J. Wentworth, A. Zimmet, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7):696\u2013703.","DOI":"10.1111\/apt.14937"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0016","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dld.2021.06.023_bib0017","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.023_bib0018","doi-asserted-by":"crossref","unstructured":"M. Alexander, D. Ansell, A. Pasqua, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Medicine 2019;17:19.","DOI":"10.1186\/s12916-019-1321-x"},{"issue":"2","key":"10.1016\/j.dld.2021.06.023_bib0019","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.dld.2021.06.023_bib0020","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.dld.2021.06.023_bib0021","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.cgh.2019.01.027","article-title":"Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis","volume":"17","author":"Pelusi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2021.06.023_bib0022","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/hep.29660","article-title":"Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies","volume":"67","author":"Simon","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0023","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.dld.2021.06.023_bib0024","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/hep.22793","article-title":"Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States","volume":"49","author":"Hassan","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dld.2021.06.023_bib0025","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"Tr\u00e9po","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0026","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals","volume":"7","author":"Donati","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.dld.2021.06.023_bib0028","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/liv.13972","article-title":"Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease","volume":"39","author":"Pelusi","year":"2019","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0029","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2021.06.023_bib0031","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jhep.2014.12.028","article-title":"Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance","volume":"62","author":"Anstee","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2021.06.023_bib0032","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2014.10.048","article-title":"HCC and liver disease risks in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance","volume":"62","author":"Krawczyk","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0033","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cmet.2015.12.015","article-title":"Obesity and cancer: the oil that feeds the flame","volume":"23","author":"Font-Burgada","year":"2016","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.dld.2021.06.023_bib0034","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"Ibrahim","year":"2018","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.dld.2021.06.023_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ccr.2006.12.016","article-title":"Deletion of NEMO\/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma","volume":"11","author":"Luedde","year":"2007","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.dld.2021.06.023_bib0036","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","article-title":"Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC","volume":"175","author":"Grohmann","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.dld.2021.06.023_bib0037","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2016.10.007","article-title":"Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis","volume":"30","author":"Kettner","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0038","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0039","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dld.2021.06.023_bib0040","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.dld.2021.06.023_bib0041","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.transproceed.2016.01.077","article-title":"Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis","volume":"48","author":"Gr\u0105t","year":"2016","journal-title":"Transplant Proc"},{"issue":"7384","key":"10.1016\/j.dld.2021.06.023_bib0042","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.dld.2021.06.023_bib0043","doi-asserted-by":"crossref","unstructured":"S. Mittal, H.B. El-Serag, Y.H. Sada, et al. Hepatocellular carcinoma in the absence of cirrhosis in US veterans is associated with non-alcoholic fatty liver disease. 2016;14:124\u201331.","DOI":"10.1016\/j.cgh.2015.07.019"},{"issue":"4","key":"10.1016\/j.dld.2021.06.023_bib0044","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/hep.31157","article-title":"Risk of cirrhosis and hepatocellular cancer in patients with NAFLD and normal liver enzymes","volume":"72","author":"Natarajan","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.dld.2021.06.023_bib0046","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.06.023_bib0047","doi-asserted-by":"crossref","unstructured":"Taylor R.S., Taylor R.J., Bayliss S., et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis 2020;158:1611\u20131625.","DOI":"10.1053\/j.gastro.2020.01.043"},{"issue":"7","key":"10.1016\/j.dld.2021.06.023_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0158817","article-title":"An animal model for the juvenile non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"11","author":"Marin","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.dld.2021.06.023_bib0049","doi-asserted-by":"crossref","unstructured":"O'Hara J., Finnegan A., Dhillon H., et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. J HEP 2020;2(5):18. 2100142. doi:10.1016\/j.jhepr.2020.100142. eCollection 2020 Oct.","DOI":"10.1016\/j.jhepr.2020.100142"},{"key":"10.1016\/j.dld.2021.06.023_bib0050","doi-asserted-by":"crossref","unstructured":"Tapper E.B., Hunink M.G.M., Afdhal N.H., Lai M., Sengupta N.et al. Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score. PLoS ONE 2016;11(2):112. e0147237. doi:10.1371\/journal.pone.0147237. eCollection 2016.","DOI":"10.1371\/journal.pone.0147237"},{"key":"10.1016\/j.dld.2021.06.023_bib0051","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study","author":"Simon","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.06.023_bib0052","doi-asserted-by":"crossref","unstructured":"V. Paradis, S. Zalinski, E. Chelbi, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. 2009;49(3):9.","DOI":"10.1002\/hep.22734"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0053","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0035-1562942","article-title":"Diagnosis and assessment of NAFLD: definitions and histopathological classification","volume":"35","author":"Burt","year":"2015","journal-title":"Semin Liver Dis"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0054","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","article-title":"Molecular and histological correlations in liver cancer","volume":"71","author":"Calderaro","year":"2019","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0055","doi-asserted-by":"crossref","first-page":"e0171922","DOI":"10.1371\/journal.pone.0171922","article-title":"Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.dld.2021.06.023_bib0056","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/his.12343","article-title":"Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients","volume":"64","author":"Shibahara","year":"2014","journal-title":"Histopathology"},{"issue":"11","key":"10.1016\/j.dld.2021.06.023_bib0057","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1097\/PAS.0b013e3181f31caa","article-title":"Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD\/NASH","volume":"34","author":"Salomao","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.dld.2021.06.023_bib0058","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/his.12479","article-title":"Steatohepatitic hepatocellular carcinoma: a metabolic syndrome-associated carcinoma","volume":"67","author":"Jain","year":"2015","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0059","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.dld.2013.09.018","article-title":"Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity?","volume":"46","author":"Nascimbeni","year":"2014","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.dld.2021.06.023_bib0060","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1053\/j.gastro.2016.11.042","article-title":"Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation","volume":"152","author":"Nault","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.dld.2021.06.023_bib0061","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2018.12.014","article-title":"Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study","volume":"70","author":"Baumeister","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2021.06.023_bib0062","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/ajg.2013.7","article-title":"Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"9436","key":"10.1016\/j.dld.2021.06.023_bib0063","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(04)16936-5","article-title":"Mortality and incidence of cancer during 10-year follow-up of the scandinavian simvastatin survival study (4S)","volume":"364","author":"Strandberg","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12030671","article-title":"Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"12","author":"Islam","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.dld.2021.06.023_bib0065","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1007\/s11695-018-3431-5","article-title":"Bariatric surgery and hepatocellular carcinoma: a propensity score-matched analysis","volume":"28","author":"Njei","year":"2018","journal-title":"Obes Surg"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0066","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/apt.13841","article-title":"Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"45","author":"Simmons","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dld.2021.06.023_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0204412","article-title":"Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis","volume":"13","author":"Ioannou","year":"2018","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0068","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis","volume":"18","author":"Best","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2021.06.023_bib0069","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.25536","article-title":"Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease","volume":"55","author":"Reddy","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/bjs.8963","article-title":"Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome","volume":"100","author":"Cauchy","year":"2013","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0071","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2015.01.024","article-title":"Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC","volume":"63","author":"Vigan\u00f2","year":"2015","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2021.06.023_bib0072","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.21873\/anticanres.13760","article-title":"Diabetes mellitus and\/or nonalcoholic steatohepatitis-related hepatocellular carcinoma showed favorable surgical outcomes after hepatectomy","volume":"39","author":"Liang","year":"2019","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.dld.2021.06.023_bib0073","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.08.565","article-title":"Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma","volume":"229","author":"Koh","year":"2019","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.dld.2021.06.023_bib0074","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11605-018-04071-2","article-title":"Liver resection for hepatocellular carcinoma in non-alcoholic fatty liver disease: a multicenter propensity matching analysis with HBV-HCC","volume":"24","author":"Yang","year":"2020","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0075","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.dld.2021.06.023_bib0076","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/apt.15464","article-title":"Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study","volume":"50","author":"Gawrieh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dld.2021.06.023_bib0077","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European liver transplant registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.dld.2021.06.023_bib0078","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1158\/1078-0432.CCR-20-1497","article-title":"Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma","volume":"26","author":"Bassaganyas","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2021.06.023_bib0079","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.31479","article-title":"Improving the efficacy of liver cancer immunotherapy: the power of combined preclinical and clinical studies","volume":"73","author":"Feng","year":"2021","journal-title":"Hepatology"},{"issue":"7854","key":"10.1016\/j.dld.2021.06.023_bib0080","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"issue":"3_suppl","key":"10.1016\/j.dld.2021.06.023_bib0081","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo)\u202f+\u202fbevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0082","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.dld.2021.06.023_bib0083","doi-asserted-by":"crossref","unstructured":"B. Scheiner, M.M. Kirstein, F. Hucke, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther 2019;49(10):1323-1333.","DOI":"10.1111\/apt.15245"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0084","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.dld.2021.06.023_bib0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2021.06.023_bib0086","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.numecd.2020.02.016","article-title":"Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy","volume":"30","author":"Petta","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.dld.2021.06.023_bib0087","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821003376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821003376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:16:48Z","timestamp":1761625008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821003376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1590865821003376"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.06.023","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}